MoonLake Immunotherapeutics (MLTX) Cash from Operations Growth (1y) (2022 - 2026)
Powered by 
Analysis
MoonLake Immunotherapeutics (MLTX) Cash from Operations Growth (1y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 42.76% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 75.58% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 151.70% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 100.14% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 56.79% |
| 10 | MoonLake Immunotherapeutics | 1.10 Bn | 565.05 Mn | - | -1.89% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.89% |
| Mar 31, 2026 | -73.80% |
| Dec 31, 2025 | -21.29% |
| Sep 30, 2025 | -76.23% |
| Jun 30, 2025 | -95.52% |
| Mar 31, 2025 | -155.15% |
| Dec 31, 2024 | -292.68% |
| Sep 30, 2024 | -173.24% |
| Jun 30, 2024 | -129.38% |
| Mar 31, 2024 | -65.64% |
| Dec 31, 2023 | -6.45% |
| Sep 30, 2023 | 1.08% |
| Jun 30, 2023 | 41.43% |
| Mar 31, 2023 | 36.38% |
| Dec 31, 2022 | 67.03% |
| Sep 30, 2022 | -363.27% |
| Jun 30, 2022 | 18.89% |
| Mar 31, 2022 | -13,060.13% |